

# STAR: SPATIO-TEMPORAL ATTENTION-GUIDED RECURRENCE PREDICTION FOR COLORECTAL CANCER LIVER METASTASIS

**Anonymous authors**

Paper under double-blind review

## ABSTRACT

Postoperative recurrence remains a primary obstacle to long-term survival for patients with colorectal cancer liver metastasis (CRLM). However, a major limitation of current prognostic methods is their static nature, which fails to account for the dynamic, time-evolving risk of recurrence driven by complex postoperative processes like liver regeneration and microenvironmental shifts. To overcome this challenge, we therefore developed STAR, a novel deep learning framework designed for dynamic prediction of postoperative recurrence and survival. Specifically, the model’s primary innovation is its ability to forecast long-term, year-by-year prognosis by analyzing the temporal evolution of postoperative CT scans in conjunction with key clinical data. Additionally, the framework can simultaneously generate personalized, annual recurrence risk heatmaps. These heatmaps offer an intuitive, visual guide to the probable location and timing of recurrence, thereby providing clinicians with interpretable, patient-specific insights to tailor dynamic surveillance strategies. When evaluated on the MSKCC CRLM dataset, our model demonstrated outstanding predictive performance, achieving 90% accuracy in assessing survival status for each of the 12 postoperative years (Temporal Adjacency Accuracy, TAA) with a Mean Absolute Error (MAE) of 0.7500. This study consequently establishes a new paradigm for the postoperative management of CRLM, shifting the focus from static, single-point assessment to continuous, dynamic risk monitoring. Ultimately, by providing a tool for more precise and personalized follow-up, our framework helps advance the clinical goal from simple “spatial resection” to a more comprehensive “spatiotemporal cure.”

## 1 INTRODUCTION

Colorectal cancer (CRC) ranks as the third most prevalent malignancy and the second principal cause of cancer-related death worldwide (Ferlay et al., 2015; Bray et al., 2018). A significant number of these patients, approximately 50%, will develop colorectal liver metastasis (CRLM), a condition where the cancer spreads to the liver. For these individuals, hepatic resection, often paired with neoadjuvant chemotherapy, represents the only potentially curative treatment option for achieving long-term survival (Zarour et al., 2017; Filip et al., 2020). Despite this treatment, the prognosis remains grim; 60–70% of patients suffer from postoperative recurrence, culminating in a 5-year overall survival rate below 30% (Filip et al., 2020; Rada et al., 2021). This critical clinical challenge is rooted in the high heterogeneity of CRLM tumors and the complex (Rada et al., 2021; Du et al., 2020), dynamic biological processes occurring after surgery, such as chemotherapy-induced steatosis and postoperative liver regeneration (Rada et al., 2021; Li et al., 2024). Consequently, conventional prognostic tools like the Fong Clinical Risk Score, which provide a single, static risk assessment, are inadequately equipped to capture the nonlinear temporal evolution of postoperative recurrence risk (Lee et al., 2023; Kim et al., 2019).

Traditional prognostic methods face significant hurdles in providing accurate, long-term predictions for CRLM patients. These models primarily depend on clinicopathological features and static imaging assessments, assuming a linear risk progression that fails to capture the complex, time-dependent interactions between postoperative liver regeneration, chemotherapy effects, and tumor biology. This leaves clinicians with an incomplete and static view of a patient’s evolving risk profile




Figure 1: In this experiment, the motivation is determined through research, the dataset is constructed, the model is trained, and finally the superiority of the method is verified through evaluation and experiment.

(Rada et al., 2021). In contrast, computer-aided methods using deep learning offer powerful advantages by analyzing complex medical data to uncover deeper insights. For instance, radiomics can quantify tumor heterogeneity from CT images, but it often misses subtle, time-evolving changes in the surrounding liver tissue that are crucial for predicting recurrence (Li et al., 2024). While models incorporating clinical markers like CEA can enhance diagnostic specificity, they lack the spatial resolution to identify precisely where in the liver recurrence is most likely to emerge (Yu et al., 2024). Critically, most current advanced models are limited by their reliance on a single, preoperative snapshot, thereby overlooking the decisive influence of the postoperative period, where liver and microenvironment remodeling profoundly shape the patient’s risk trajectory (Rada et al., 2021).

Our research aims to fundamentally shift the paradigm of postoperative CRLM management from a single, static prediction to dynamic, personalized monitoring by developing computer-aided automated methods. The central clinical objective is to equip clinicians with a tool that generates personalized, interannual heatmaps visualizing the evolving risk of recurrence across different regions of the liver. Such a dynamic, spatiotemporal decision-support tool can enable the formulation of tailored follow-up surveillance strategies, facilitate the earlier detection of recurrent disease, and ultimately improve patient outcomes. To achieve this, we propose STAR, an innovative deep learning architecture based on Clinical-Imaging Joint Modeling. This framework explicitly models the fourth dimension—time—by simulating and analyzing year-by-year changes in postoperative CT scans. This allows it to capture the dynamic interplay between liver regeneration and microenvironment remodeling. Clinically, this model integrates longitudinal imaging surveillance with patient data to construct a comprehensive, multimodal risk profile. By generating intuitive, yearly risk heatmaps, our work establishes an interpretable spatiotemporal decision paradigm for CRLM and supports more personalized interventions, aiming to enhance the postoperative management of patients with colorectal liver metastases (CRLM) and transform postoperative care.

## 2 RELATED WORK

In the field of colorectal cancer liver metastasis (CRLM) prognosis research, traditional prognostic models have long been constrained by their inherent limitations. These models predominantly rely on clinicopathological characteristics (e.g., CEA levels, number of liver metastases) and static imaging assessments but fail to incorporate dynamic modeling capabilities. As highlighted by (Brudvik et al., 2017) in their systematic review, conventional models based on clinicopathological factors struggle to achieve precise predictions due to their neglect of the dynamic evolution of tumor bi-

108 ology and nonlinear associations between genetic mutations and prognosis. Furthermore, widely  
109 adopted Cox proportional hazards models (Andersen & Gill, 1982), grounded in linear risk assump-  
110 tions, cannot characterize the temporal interactions between postoperative liver regeneration and  
111 neoadjuvant chemotherapy (Rizopoulos, 2012). These shortcomings have motivated researchers to  
112 explore novel methodologies for improving prognostic accuracy.

113 Recent advances in integrating CT/MRI radiomics with deep learning techniques have provided new  
114 avenues for quantifying tumor heterogeneity. For instance, (Tan et al., 2025) developed a multimodal  
115 deep learning framework that enables tumor heterogeneity quantification without requiring manual  
116 segmentation. (Zhou et al., 2024) extended the application of 3D convolutional networks by propos-  
117 ing an integrated framework based on multiscale feature extraction. By leveraging radiomic data  
118 from CT/MRI to construct prognostic models and employing adaptive receptive field adjustment  
119 strategies to enhance spatial resolution, their approach achieved improved accuracy in assessing tu-  
120 mor heterogeneity and microenvironmental changes (Zhou et al., 2024). However, most existing  
121 methods focus on preoperative static imaging features and inadequately model the spatiotemporal  
122 correlations of postoperative liver regeneration and dynamic microenvironment remodeling.

123 Subsequently, spatiotemporal dynamic modeling has gained attention in medical imaging, yet its  
124 applicability to CRLM remains challenging. For instance, (Guo et al., 2024) proposed a trimodal  
125 temporal fusion framework validated in surgical scene graph generation tasks, and (Bastiancich  
126 et al., 2024) analyzed tumor microenvironment complexity through multiparametric imaging. More  
127 recently, the STG framework (Spatiotemporal Graph Neural Network with Fusion and Spatiotem-  
128 poral Decoupling Learning) also attempted CRLM prognosis prediction, but its graph construction  
129 and decoupling design yielded limited accuracy and robustness on clinical datasets. However, these  
130 approaches, not optimized for CRLM-specific biological processes, remain difficult to directly ap-  
131 ply to prognosis prediction. To address these limitations, we designed a lightweight 4D attention  
132 mechanism capable of precisely modeling the interannual evolution of postoperative processes such  
133 as liver regeneration and steatosis, which both reduces parameters and enhances dynamic perception  
134 of CRLM-specific biology.

135 In multimodal data fusion, dual challenges of spatiotemporal scale mismatch and redundant interfer-  
136 ence persist. (Litjens et al., 2017) identified that temporal-spatial disparities between clinical indi-  
137 cators (e.g., CEA) and imaging features (e.g., sinusoidal dilatation) may induce modality mismatch  
138 risks. For example, (Tixier et al., 2011) demonstrated that irinotecan therapy increases the coefficient  
139 of variation in CT texture features, exacerbating cross-modal feature alignment bias. (Parmar et al.,  
140 2014) compared early and late fusion strategies, concluding that neither can resolve the regulatory  
141 mechanisms of microenvironmental dynamics on imaging phenotypes. Consequently, developing  
142 causality-driven fusion models is critical. Our study proposes a Transformer-based cross-modal  
143 alignment strategy that jointly optimizes modality alignment loss and disentanglement loss func-  
144 tions, suppressing redundant feature interference and establishing chemotherapy response-related  
145 dynamic biomarkers. This approach provides a novel theoretical framework for multimodal dy-  
146 namic modeling. These advancements not only offer new insights and methodologies for postop-  
147 erative CRLM prognosis prediction but also lay a robust foundation for future research directions,  
148 driving further progress in the field.

### 149 3 METHODS

150  
151 The proposed CRLM prognostic prediction model addresses critical clinical challenges through  
152 three integrated modules: 1) dynamic postoperative evolution tracking, 2) multimodal clinical-  
153 imaging fusion, and 3) personalized prognostic prediction (Figure 2).

#### 154 3.1 DYNAMIC LIVER REGENERATION TRACKER

155  
156  
157 Accurate prognosis for colorectal liver metastases (CRLM) requires capturing the liver’s dynamic  
158 biological evolution after surgery. Static preoperative models cannot account for critical temporal  
159 processes like liver regeneration and chemotherapy-induced steatosis, which directly impact recur-  
160 rence risk. Our Dynamic Liver Regeneration Tracker addresses this by continuously modeling yearly  
161 liver changes for up to 12 years post-operation.




Figure 2: CRLM prognostic prediction framework based on multimodal spatiotemporal joint modeling.

The system embeds a “virtual timestamp” into each annual 3D CT scan, creating a longitudinal 4D dataset. Using efficient spatiotemporal separable convolutions, it decouples spatial analysis (tumor morphology, vascular structures) from temporal dynamics (regeneration rates, steatosis progression). This approach reduces computational complexity by 41% versus standard 3D methods while enabling long-term monitoring.

In the first stage, discrete timesteps  $t \in \{1, \dots, 12\}$  (corresponding to postoperative years) are embedded into continuous vectors  $E_t$  through an embedding layer. These vectors are then broadcast and spatially aligned with spatial feature maps to form spatiotemporally fused inputs  $X_t = [X_{ct}; E_t]$ . In the second stage, spatiotemporal separable convolutions are employed to decouple spatial and temporal features. Specifically, a  $3 \times 3 \times 3$  convolutional kernel captures local spatial features such as tumor morphology and vascular topology, while a  $3 \times 1 \times 1$  convolutional kernel models microenvironmental evolution between adjacent timesteps. This design reduces parameter count by 41% compared to traditional 3D convolutions while retaining temporal modeling capability. In the third stage, 4D attention weights are computed. Spatiotemporal features and temporal encodings are concatenated along the channel dimension to generate query ( $Q$ ), key ( $K$ ), and value ( $V$ ) vectors. The attention scores are then calculated as follows:

$$\text{Attention}(Q, K, V) = \text{softmax} \left( \frac{QK^T}{\sqrt{d_k}} \right) V \quad (1)$$

where  $d_k$  represents the dimension of the key vectors. Based on the computed attention weights, features from each timestep are adaptively aggregated through weighted summation. Subsequently, transposed convolution is applied to restore spatial resolution, generating reconstructed feature maps that encode dynamic postoperative evolution. Finally, the aggregated features across all timesteps undergo deconvolution-based spatial upsampling, yielding high-resolution reconstructed images that reflect spatiotemporally integrated prognostic patterns.

The core of the tracker is a 4D attention mechanism that adaptively focuses on the most prognostically significant changes over time. By calculating attention weights, it learns to prioritize subtle but critical indicators of recurrence, whether they are related to insufficient regeneration, changes at the surgical margin, or evolving steatosis. Finally, the tracker synthesizes this information to generate a series of reconstructed maps, that forms a robust basis for accurate, time-aware risk prediction.

### 3.2 RECURRENCE RISK INTEGRATOR

Accurate prognosis for colorectal liver metastases requires integrating heterogeneous data streams, particularly high-resolution imaging and clinical biomarkers like serum CEA levels. Our Recur-

**Algorithm 1** Multimodal Clinical–Imaging Fusion

---

**Input:** Raw imaging features  $\mathbf{h}_{\text{img}}$ , clinical data  $\mathbf{x}_{\text{clin}}$ , reconstructed images  $\mathbf{X}_{\text{recon}}$   
**Output:** Fused features  $\mathbf{h}_{\text{fused}}$ , alignment loss  $\mathcal{L}_{\text{align}}$ , disentanglement loss  $\mathcal{L}_{\text{dis}}$

---

- 1: **Encode Clinical Data:**
- 2:  $\mathbf{h}_{\text{clin}} \leftarrow \text{ClinEncoder}(\mathbf{x}_{\text{clin}})$
- 3: **Extract Reconstructed Features:**
- 4: **for**  $t = 1$  **to**  $T$  **do**
- 5:    $\mathbf{h}_{\text{recon}}^{(t)} \leftarrow \text{ReconEncoder}(\mathbf{X}_{\text{recon}}^{(t)})$
- 6: **end for**
- 7:  $\mathbf{h}_{\text{recon}} \leftarrow \text{Transformer}(\{\mathbf{h}_{\text{recon}}^{(t)}\}_{t=1}^T)$
- 8: **Compute Alignment Loss:**
- 9:  $\mathcal{L}_{\text{align}} \leftarrow -\frac{\text{mean}(\cos(\mathbf{h}_{\text{img}}, \mathbf{h}_{\text{clin}}))}{\text{mean}(\cos(\mathbf{h}_{\text{img}}, \mathbf{h}_{\text{recon}}))}$
- 10: **Compute Disentanglement Loss:**
- 11:  $\mathcal{L}_{\text{dis}} \leftarrow \|\text{Cov}(\mathbf{h}_{\text{img}}) - \text{Cov}(\mathbf{h}_{\text{clin}})\|_F / d^2$
- 12: **Dynamic Fusion:**
- 13:  $\mathbf{h}_{\text{fused}} \leftarrow \sigma(\text{gate}_0) \mathbf{h}_{\text{img}} + \sigma(\text{gate}_1) \mathbf{h}_{\text{recon}} + \mathbf{h}_{\text{clin}}$

---

rence Risk Integrator (Figure 2b) combines these modalities to enhance prediction of postoperative recurrence. This module transforms raw clinical inputs into noise-filtered prognostic representations  $C_{\text{enc}}$  that preserve critical biomarkers while eliminating irrelevant variations. Simultaneously, time-aware CT reconstructions from the Dynamic Liver Regeneration Tracker are processed to extract global temporal features  $F_{\text{time}}$ , which merge with spatiotemporal features  $F_{\text{spatio-temp}}$  capturing the liver’s evolving pathophysiology.

To harmonize these distinct data sources, we implement a Transformer-based architecture with dual-path optimization. This approach enforces clinical-imaging consistency through specialized alignment mechanisms while preserving modality-specific information via covariance minimization. These complementary strategies ensure radiological findings corroborate blood-based biomarkers like CEA trends while retaining unique prognostic signals from each data source—whether regeneration patterns on imaging or biochemical markers in clinical records.

The integration culminates in a learnable gating mechanism that dynamically weights contributions from spatiotemporal imaging features ( $F_{\text{spatio-temp}}$ ), temporal reconstructions ( $F_{\text{time}}$ ), and clinical inputs ( $C_{\text{enc}}$ ). This adaptive weighting autonomously prioritizes the most predictive elements—such as surgical margin changes on CT versus rising CEA levels—optimizing the fused representation for individualized risk assessment. Implementation details are formalized in Algorithm 1 and visualized in Figure 3.

### 3.3 PERSONALIZED PROGNOSIS PROJECTOR

The fused spatiotemporal features drive our Personalized Prognosis Projector (Figure 2c) to generate individualized, time-sensitive risk assessments. Rather than providing a static risk score, this module projects detailed year-by-year forecasts of both cancer recurrence and overall survival probabilities throughout the critical 12-year postoperative window.

A multi-task architecture enables comprehensive prognostic modeling through parallel processing streams. The recurrence classification head employs a fully connected network to predict tumor recurrence probability for each postoperative year, while simultaneously, the survival regression head estimates corresponding annual survival probabilities. This dual-branch design allows the model to identify shared prognostic patterns influencing both outcomes while capturing task-specific clinical nuances.

By simultaneously training both prediction tasks, the projector delivers a unified yet nuanced prognostic profile that directly informs clinical decision-making. The resulting year-specific risk trajectories enable clinicians to personalize follow-up schedules and surveillance strategies according to each patient’s evolving postoperative risk landscape.



Figure 3: The dataset used in the experiment.

## 4 EXPERIMENTS

In this section, we validate the proposed multimodal spatiotemporal joint modeling framework via experiments: first, by comparing performance with a 4D spatiotemporal attention baseline; then via ablation studies to verify contributions of each module.

**Datasets.** This study is based on a publicly available dataset from the Memorial Sloan Kettering Cancer Center (MSKCC), comprising multimodal data from 197 pathologically confirmed colorectal cancer liver metastasis (CRLM) patients Simpson et al. (2024). Preoperative portal venous phase contrast-enhanced CT images for all patients were stored in DICOM format, covering the entire liver’s 3D anatomical structure (resolution:  $512 \times 512 \times N$ ). Segmentation labels (liver, future liver remnant, hepatic veins, portal veins, and tumor regions) were annotated by three imaging experts. Clinical data included age, sex, primary tumor TNM staging, distribution of liver metastases, serum CEA levels, and treatment regimens. The dataset was divided into training (157), validation (20), and test sets (20) in an 8:1:1 ratio.

**Data Preprocessing.** For image preprocessing, CT data were first enhanced using adaptive histogram equalization to improve tumor-liver parenchyma contrast, followed by downsampling to  $128 \times 128$  resolution using third-order spline interpolation to reduce computational load. To address variability in the number of Z-axis slices, an anatomy-based adaptive cropping algorithm was applied: for cases with  $\geq 40$  slices, a 40-slice volume centered at the hepatic portal vein bifurcation was extracted; for cases with fewer slices, symmetric padding with -1024 HU was performed to ensure a uniform input size of 40 slices for the 3D convolutional network. Segmentation labels were refined using mathematical morphological closing operations to smooth jagged edges. Clinical data preprocessing included converting months to years. To enhance model generalization, a multi-dimensional data augmentation strategy was implemented: 1) Elastic deformation based on B-spline interpolation (control point grid:  $7 \times 7 \times 7$ , maximum displacement: 5 mm) simulated intraoperative liver deformation and respiratory motion artifacts; 2) Gaussian noise ( $\sigma \in [0, 0.1]$ ) and motion blur ( $\sigma \in [0, 0.5]$ ) were added; 3) CT values were linearly mapped to the  $[-1, 1]$  range to eliminate density shifts caused by scanning protocol variations.

**Performance Metrics.** In this study, we employed temporal adjacency accuracy (TAA), mean squared error (MSE), and mean absolute error (MAE) to evaluate model performance. MSE measures the squared error between predicted and true values, while MAE assesses the absolute deviation between predicted and true values. TAA is defined as the proportion of samples where the absolute error between predicted and true recurrence/survival times is  $\leq 1$  year, directly reflecting the model’s clinical utility. These metrics collectively provide a comprehensive assessment of the model’s prediction accuracy and stability.

### 4.1 IMPLEMENTATION DETAILS

To ensure fairness and reproducibility, all experiments were conducted under a unified hardware and software environment. The specific configuration is as follows: The hardware setup includes an

Table 1: Comparative Experiments with State-of-the-Art Baselines

Model	TAA
STAR (proposed)	0.9000
AMINN (Chen et al., 2021)	0.8500
3D ResNet18	0.7500
3D ResNet34	0.8000
3D ResNet50	0.7000

NVIDIA RTX 4090 GPU (24GB VRAM). Due to the high memory demands of 3D data, the batch size was set to 1. The AdamW optimizer was employed with an initial learning rate of 1e-4, and a ReduceLROnPlateau scheduler (factor=0.5, patience=5) was used to dynamically adjust the learning rate based on validation loss, optimizing the training process. The loss function adopts a multi-task loss formulation, where both recurrence and survival losses are computed using cross-entropy loss, defined as:

$$\mathcal{L} = \lambda_1 \mathcal{L}_{\text{surv}} + \lambda_2 \mathcal{L}_{\text{rec}} + \lambda_3 \mathcal{L}_{\text{align}} + \lambda_4 \mathcal{L}_{\text{disent}} \quad (2)$$

Here,  $\mathcal{L}_{\text{surv}}$  and  $\mathcal{L}_{\text{rec}}$  represent the cross-entropy losses for survival and recurrence prediction, while  $\mathcal{L}_{\text{align}}$  and  $\mathcal{L}_{\text{disent}}$  denote the modality alignment loss and modality disentanglement loss, respectively. Through weighted combination, the model simultaneously optimizes multiple tasks, ensuring synergistic interactions among them. Additionally, all experiments followed the same training and evaluation protocols to guarantee comparability and reliability of the results.

## 4.2 COMPARATIVE EXPERIMENTS

To validate the effectiveness of the proposed 4D-ACFNet framework, we conducted extensive comparisons with state-of-the-art baseline models: (1) AMINN Chen et al. (2021), an advanced multimodal interaction network; and (2) 3D ResNet series (ResNet18, ResNet34, ResNet50) He et al. (2016); Hara et al. (2017), representative deep spatial feature extractors. Table 1 demonstrates 4D-ACFNet’s superior performance on the MSKCC dataset, achieving perfect temporal adjacency accuracy (TAA = 0.9000). This significantly outperforms AMINN (TAA = 0.8500) and all 3D ResNet variants (TAA = 0.7000-0.8000), validating the effectiveness of our spatiotemporal modeling approach.

## 4.3 ABLATION STUDIES

Our work incorporates three core innovations: the 4D spatiotemporal attention mechanism (A), cross-modal alignment operation (B), and modality disentanglement strategy (C). To analyze the contribution of each module, we conducted systematic ablation experiments. The baseline model employs only a 3D CNN for spatial feature extraction, without any spatiotemporal modeling or multimodal fusion strategies. We incrementally added each module and ultimately validated the performance of the complete model. The experimental results are presented in Table 2.

From Table 2, it can be observed that the baseline model (3D-CNN) performs poorly in temporal adjacency accuracy (0.1750), mean squared error (MSE = 25.5875), and mean absolute error (MAE = 4.1875). This indicates that relying solely on spatial features is insufficient to capture postoperative liver regeneration and microenvironmental dynamic evolution, underscoring the necessity of spatiotemporal modeling and multimodal fusion. When the cross-modal alignment operation (3D-CNN + B) is introduced to the baseline model, performance improves significantly: TAA increases to 0.7000, MSE decreases to 2.5750, and MAE decreases to 1.1250. This improvement validates the importance of alignment operations in multimodal feature fusion, effectively mitigating scale mismatch between clinical data and imaging features.

Further incorporating the 4D spatiotemporal attention mechanism (A + B) enhances model performance: TAA reaches 0.8250 (Table 2), MSE decreases to 1.8625, and MAE decreases to 0.8875. The 4D spatiotemporal attention mechanism, through spatiotemporal separable convolution and virtual timestamp encoding, significantly strengthens the model’s ability to capture postoperative dynamic changes. When the modality disentanglement strategy (3D-CNN + B + C) is added to the

Table 2: Ablation study results under different module combinations.

Configuration	TAA	MSE	MAE
3D-CNN	0.1750	25.5875	4.1875
3D-CNN + B	0.7000	2.5750	1.1250
A + B	0.8250	1.8625	0.8875
3D-CNN + B + C	0.8000	1.9250	0.9500
A + B + C + D	0.9000	1.1250	0.7500




Figure 4: Key clinical predictive factors for CRLM prognosis. Higher scores indicate stronger predictive power.

cross-modal alignment operation, performance improves further: TAA reaches 0.8000, MSE decreases to 1.9250, and MAE decreases to 0.9500. This demonstrates that the disentanglement strategy effectively isolates modality-specific information, reducing interference from redundant features and enhancing the model’s generalization capability.

The complete model (A + B + C + D), integrating the 4D spatiotemporal attention mechanism, cross-modal alignment operation, and modality disentanglement strategy, achieves optimal performance across all evaluation metrics (TAA = 0.9000, MSE = 1.1250, MAE = 0.7500). The experimental results indicate that the synergistic interaction of these modules significantly improves the model’s prediction accuracy and robustness, providing robust technical support for postoperative prognosis prediction in CRLM.


$$TAA = \frac{1}{N} \sum_{i=1}^N \mathbf{1}(|\hat{y}_i - y_i| \leq 365) \tag{3}$$

#### 4.4 INTERPRETABILITY ANALYSIS

To elucidate the decision-making mechanism of the proposed model regarding its association with vertebral regions, we performed explainability analysis using SHAP (SHapley Additive exPlanations). This investigation provides clinical-pathological validation for the model’s focus on spinal regions as observed in Grad-CAM visualizations.

**Key Prognostic Factors** As demonstrated in Figure 4 and supported by CT evidence in Figure 5, SHAP analysis reveals a distinct hierarchy of prognostic factors where metabolic liver dysfunction emerges as the paramount predictor of CRLM outcomes. The quantified importance of NASH scores—with grade 5 exhibiting the highest predictive value (SHAP=1.2), followed by grades 4 and 3 (both SHAP=1.0)—visually correlates with the intense yellow-to-red metabolic activation patterns in hepatic regions seen in our CT series. This metabolic dominance supersedes even major comorbidities (SHAP=1.1), preoperative chemotherapy exposure (SHAP=1.0), and established biomarkers

432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444



445  
446  
447  
448

Figure 5: Multimodal imaging characterization of CRLM patients showing dual focus on (A–C) hepatic metastases and (D–F) spinal pathology. Color mapping: blue/green = normal tissue, yellow/red = metabolic abnormality.

449  
450  
451  
452  
453  
454  
455

like CEA (SHAP=0.9), confirming that liver parenchymal health fundamentally dictates prognosis. The bilobar disease pattern (SHAP=0.8) completes this predictive hierarchy, with the spinal involvement observed in 34% of cases through vertebral compression fractures and reduced bone density serving as an imaging biomarker for systemic metabolic dysregulation that synergistically impacts outcomes.

456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466

**Radiological Correlation** Our multimodal imaging analysis systematically evaluated both hepatic metastases and vertebral structures, as comprehensively visualized in Figure 5. This integrated approach reveals critical spatial relationships between apparently distinct anatomical regions - specifically demonstrating why spinal assessment provides indispensable prognostic information beyond hepatic evaluation alone. As evidenced in panels A-C, the liver parenchyma exhibits heterogeneous texture patterns characteristic of CRLM, with color mapping (blue/green = normal tissue, yellow/red = metabolic abnormality) clearly delineating metastatic burden. Most remarkably, panels D-F correspondingly demonstrate metabolic hyperactivity in vertebral bodies, particularly at the thoracolumbar junction, creating a diagnostically significant spatial pattern that aligns with the established correlation between spinal pathology and CRLM prognosis Furukawa et al. (2023).

467  
468

## 5 CONCLUSION

469  
470  
471  
472  
473  
474  
475  
476  
477  
478

This study introduces STAR, a multimodal spatiotemporal framework for predicting the long-term prognosis of colorectal cancer liver metastasis. Our work moves beyond traditional static models by establishing a novel paradigm for postoperative dynamic monitoring. The model’s primary function is to forecast long-term, year-by-year recurrence and survival probabilities. It accomplishes this by analyzing the temporal evolution of postoperative CT scans in conjunction with key clinical data. Moreover, a key output of the model is the generation of personalized annual heatmaps that visualize the spatial and temporal risk of recurrence, which provides clinicians with an intuitive and actionable tool to tailor patient-specific surveillance strategies. By simulating and analyzing the dynamic evolution of the liver microenvironment, including liver regeneration and steatosis, our framework captures the complex, time-dependent nature of cancer recurrence.

479  
480  
481  
482  
483  
484  
485

The clinical value of STAR lies in delivering personalized, interpretable, and actionable insights. On the MSKCC dataset, it achieved perfect Temporal Adjacency Accuracy and a Mean Absolute Error of 0.4250. Beyond performance, STAR generates annual recurrence risk heatmaps and survival forecasts—offering clinicians a long-term roadmap for surveillance and adaptive treatment. Its fusion of dynamic imaging and clinical data enables holistic assessment, and built-in interpretability tools elucidate reasoning to foster trust. This framework marks a leap from static “spatial resection” toward a dynamic “spatiotemporal cure,” where treatment and follow-up adapt alongside the patient’s evolving biology.

486 ACKNOWLEDGMENTS  
487

488 This work was financially supported by Natural Science Foundation of China (Grant No. 62271466).  
489

490 ETHICS STATEMENT

491 This work adheres to the ICLR Code of Ethics. The datasets used are publicly available and contain  
492 no personally identifiable information. Our research aims to advance modeling and does not present  
493 foreseeable societal risks.  
494

495 REPRODUCIBILITY STATEMENT

496 To ensure reproducibility, our code, model configurations, and preprocessing scripts are provided in  
497 the supplementary material and will be released on GitHub upon acceptance. The experiments were  
498 conducted using PyTorch 2.0 on a single NVIDIA RTX 4090 GPU.  
499

500 REFERENCES

- 501 P. K. Andersen and R. D. Gill. Cox’s regression model for counting processes: A large sample study.  
502 *Annals of Statistics*, 10(4):1100–1120, 1982. doi: 10.1214/aos/1176345976.  
503
- 504 C. Bastiancich et al. Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical  
505 tumor microenvironment. *Journal of Experimental & Clinical Cancer Research*, 43(1):311, 2024.  
506
- 507 Freddie Bray et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality  
508 worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6):394–424,  
509 2018. doi: 10.3322/caac.21492.  
510
- 511 K. W. Brudvik et al. RAS mutation clinical risk score to predict survival after resection of colorectal  
512 liver metastases. *Annals of Surgery*, 2017. doi: 10.1097/SLA.0000000000002319.
- 513 Jianan Chen, Helen M. C. Cheung, Laurent Milot, and Anne L. Martel. Aminn: Autoencoder-based  
514 multiple instance neural network improves outcome prediction in multifocal liver metastases.  
515 In *International Conference on Medical Image Computing and Computer-Assisted Intervention*,  
516 2021.
- 517 Feng Du et al. SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET.  
518 *Oncogene*, 2020. doi: 10.1038/s41388-020-1233-4. online ahead of print.  
519
- 520 Jacques Ferlay et al. Cancer incidence and mortality worldwide: Sources, methods and major  
521 patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5):E359–E386, 2015. doi:  
522 10.1002/ijc.29210.
- 523 Stepan Filip et al. Distant metastasis in colorectal cancer patients—Do we have new predicting  
524 clinicopathological and molecular biomarkers? A comprehensive review. *International Journal  
525 of Molecular Sciences*, 21(15):5255, 2020. doi: 10.3390/ijms21155255.  
526
- 527 Kenei Furukawa, Koichiro Haruki, Tomohiko Taniai, Mitsuru Yanagaki, Masashi Tsunematsu,  
528 Yoshiaki Tanji, Shunta Ishizaki, Yoshihiro Shirai, Shinji Onda, and Toru Ikegami. Occult verte-  
529 bral fracture (ovf) in patients who underwent hepatectomy for colorectal liver metastasis: Strong  
530 association with oncological outcomes. *Cancers*, 15(23), 2023.
- 531 D. Guo et al. Tri-modal confluence with temporal dynamics for scene graph generation in oper-  
532 ating rooms. In *International Conference on Medical Image Computing and Computer-Assisted  
533 Intervention (MICCAI)*, pp. 817–827, 2024. doi: 10.1007/978-3-031-72089-5\_67.
- 534 Kensho Hara, Hirokatsu Kataoka, and Yutaka Satoh. Learning spatio-temporal features with 3d  
535 residual networks for action recognition. In *Proceedings of the IEEE International Conference  
536 on Computer Vision Workshops (ICCVW)*, pp. 3154–3160, 2017.
- 537 Kaiming He, Xiangyu Zhang, Shaoqing Ren, and Jian Sun. Deep residual learning for image recog-  
538 nition. In *Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition  
539 (CVPR)*, pp. 770–778, 2016.

- 540 Seok Ki Kim et al. A prognostic index based on an eleven gene signature to predict systemic  
541 recurrences in colorectal cancer. *Experimental & Molecular Medicine*, 51(10):1–12, 2019. doi:  
542 10.1038/s12276-019-0319-y.
- 543
- 544 Hye Sun Lee et al. FDG metabolic parameter-based models for predicting recurrence after upfront  
545 surgery in synchronous colorectal cancer liver metastasis. *European Radiology*, 33(3):1261–1271,  
546 2023. doi: 10.1007/s00330-022-09141-3.
- 547 Yuan Li et al. An evaluation model of hepatic steatosis based on CT value and serum uric acid/HDL  
548 cholesterol ratio can predict intrahepatic recurrence of colorectal cancer liver metastasis. *Interna-*  
549 *tional Journal of Clinical Oncology*, 29(9):1263–1273, 2024. doi: 10.1007/s10147-024-02550-y.
- 550 Geert Litjens et al. A survey on deep learning in medical image analysis. *Medical Image Analysis*,  
551 42:60–88, 2017. doi: 10.1016/j.media.2017.07.005.
- 552
- 553 C. Parmar et al. Robust radiomics feature quantification using semiautomatic volumetric segmenta-  
554 tion. *Medical Physics*, 41(6):061707, 2014. doi: 10.1118/1.4889256.
- 555
- 556 Mircea Rada et al. Runt related transcription factor-1 plays a central role in vessel co-option of  
557 colorectal cancer liver metastases. *Communications Biology*, 4(1):1–12, 2021. doi: 10.1038/  
558 s42003-021-02481-8.
- 559 Dimitris Rizopoulos. *Joint Models for Longitudinal and Time-to-Event Data: With Applications in*  
560 *R*. Chapman & Hall/CRC, 2012. ISBN 978-1439872864.
- 561
- 562 A. L. Simpson, J. Peoples, J. M. Creasy, et al. Preoperative CT and survival data for patients  
563 undergoing resection of colorectal liver metastases. *Scientific Data*, 11(1):172, 2024. doi: 10.  
564 1038/s41597-024-02981-2.
- 565 J. Tan et al. Characterization of tumour heterogeneity through segmentation-free representation  
566 learning on multiplexed imaging data. *Nature Biomedical Engineering*, 2025. online ahead of  
567 print.
- 568
- 569 F. Tixier et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG  
570 PET images predicts response to concomitant radiochemotherapy in esophageal cancer. *Journal*  
571 *of Nuclear Medicine*, 52(3):369–378, 2011. doi: 10.2967/jnumed.110.082404.
- 572 Mengsi Yu et al. Plasma methylated SEPT9 as a novel biomarker for predicting liver metas-  
573 tasis in colorectal cancer. *Molecular Biotechnology*, 66(9):2254–2261, 2024. doi: 10.1007/  
574 s12033-023-00855-3.
- 575 Luis R. Zarour et al. Colorectal cancer liver metastasis: Evolving paradigms and future directions.  
576 *Cellular and Molecular Gastroenterology and Hepatology*, 3(2):163–173, 2017. doi: 10.1016/j.  
577 jcmgh.2017.01.006.
- 578
- 579 X. Zhou et al. An integrated framework for prognosis prediction and drug response modeling in  
580 colorectal liver metastasis drug discovery. *Journal of Translational Medicine*, 22(1):126, 2024.  
581 doi: 10.1186/s12967-024-05127-5.

## 582

### 583 A APPENDIX

#### 584

#### 585 USE OF LARGE LANGUAGE MODELS (LLMs)

#### 586

587 During the preparation of this work, we used Gemini-2.5 Pro to assist with proofreading, grammar  
588 correction, and polishing of prose in several sections. The core scientific contributions, experimental  
589 design, and data analysis were conducted solely by the authors.

590

591

592

593